SER

Serina Therapeutics, Inc. (SER) - Q2 2024 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2024. Serina Therapeutics, Inc. is a clinical-stage biotechnology company developing drug product candidates for neurological diseases and pain using its proprietary POZ drug delivery technology. The reporting period is significantly impacted by the consummation of a reverse recapitalization merger with AgeX Therapeutics, Inc. on March 26, 2024. Legacy Serina is the accounting acquirer. The company is classified as a smaller reporting company and an emerging growth company.

Key Financial Metrics

Note: Q2 2024 Net Income of $5.2 million is primarily driven by a $9.3 million non-cash gain from the change in fair value of Merger Warrants. Operating loss for the quarter was $3.9 million.

Material Changes vs. Prior Period

• Merger Impact: The March 26, 2024 merger resulted in the conversion of all Legacy Serina preferred stock to common stock and the assumption of AgeX liabilities, including significant debt to Juvenescence Limited.
• Expense Surge: Operating expenses increased significantly compared to the prior year. Research and Development (R&D) expenses rose 233% QoQ and 208% YTD, driven by severance, increased salaries, and patent fees. General and Administrative (G&A) expenses rose 391% QoQ and 232% YTD, largely due to legal and accounting fees associated with the merger.
• Debt Structure: The company assumed the 2022 and 2023 Secured Notes from Juvenescence. As of June 30, 2024, total debt (net of issuance costs) was approximately $11.1 million. The AgeX-Serina Note was converted to equity during the merger.
• Warrant Liability: A new warrant liability of $13.4 million was recorded related to Post-Merger and Incentive Warrants issued to stockholders, classified as liabilities and marked to market.

Guidance, Outlook, and Risks

• Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. Cash on hand ($6.1 million) plus expected proceeds from Juvenescence warrant exercises (~$10 million) are not expected to be sufficient to fund operations for the next 12 months.
• Capital Commitments: Juvenescence Limited has agreed via a Side Letter to exercise remaining Post-Merger Warrants to provide an additional $15 million in capital. $5.0 million was received in June 2024; the remaining ~$10 million is scheduled for exercise by November 30, 2024, and June 30, 2025.
• Internal Controls: The company identified material weaknesses in internal controls over financial reporting due to a lack of qualified accounting staff and reliance on manual processes at Legacy Serina. Remediation is underway.
• Outlook: The company expects to continue incurring losses and negative cash flows. Future funding will require additional equity or debt financing, which may result in dilution or restrictive covenants.

Investor Verification Checklist

• Liquidity Runway: Verify the timing and certainty of the remaining $10 million warrant exercises by Juvenescence, as this is critical to the going concern assessment.
• Debt Covenants: Review the terms of the 2022 and 2023 Secured Notes with Juvenescence, specifically regarding repayment dates (extended to Dec 31, 2024) and restrictive covenants.
• Non-Cash Gains: Understand that Q2 profitability is non-operational, driven by fair value adjustments of warrant liabilities, not revenue generation.
• Internal Controls: Monitor the progress of the remediation plan for material weaknesses in financial reporting controls.
• Merger Accounting: Note that financial statements prior to March 26, 2024, reflect Legacy Serina on a stand-alone basis, while post-merger figures include AgeX assets/liabilities.